OPKO Health, Inc.

LSE:0KCS Stock Report

Market Cap: US$1.0b

OPKO Health Management

Management criteria checks 2/4

OPKO Health's CEO is Phil Frost, appointed in Mar 2007, has a tenure of 17.75 years. total yearly compensation is $2.28M, comprised of 42.2% salary and 57.8% bonuses, including company stock and options. directly owns 36.6% of the company’s shares, worth $371.81M. The average tenure of the management team and the board of directors is 9.8 years and 15.7 years respectively.

Key information

Phil Frost

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage42.2%
CEO tenure17.8yrs
CEO ownership36.6%
Management average tenure9.8yrs
Board average tenure15.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Phil Frost's remuneration changed compared to OPKO Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$134m

Jun 30 2024n/an/a

-US$243m

Mar 31 2024n/an/a

-US$252m

Dec 31 2023US$2mUS$960k

-US$189m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$209m

Mar 31 2023n/an/a

-US$291m

Dec 31 2022US$972kUS$960k

-US$328m

Sep 30 2022n/an/a

-US$317m

Jun 30 2022n/an/a

-US$202m

Mar 31 2022n/an/a

-US$117m

Dec 31 2021US$2mUS$960k

-US$30m

Sep 30 2021n/an/a

US$76m

Jun 30 2021n/an/a

US$71m

Mar 31 2021n/an/a

US$121m

Dec 31 2020US$2mUS$960k

US$31m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$200m

Mar 31 2020n/an/a

-US$293m

Dec 31 2019US$1mUS$960k

-US$315m

Sep 30 2019n/an/a

-US$279m

Jun 30 2019n/an/a

-US$244m

Mar 31 2019n/an/a

-US$191m

Dec 31 2018US$2mUS$960k

-US$153m

Sep 30 2018n/an/a

-US$295m

Jun 30 2018n/an/a

-US$303m

Mar 31 2018n/an/a

-US$314m

Dec 31 2017US$971kUS$960k

-US$305m

Compensation vs Market: Phil's total compensation ($USD2.28M) is above average for companies of similar size in the UK market ($USD1.47M).

Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.

CEO

Phil Frost (88 yo)

17.8yrs

Tenure

US$2,277,200

Compensation

Dr. Phillip Frost, also known as Phil, M.D., Ph D., is Director of Non-Invasive Monitoring Systems, Inc. since June 01, 2023. He has been the Chairman, Chief Executive Officer and Director of OPKO Health,...

Leadership Team

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO17.8yrsUS$2.28m36.6%
$ 371.8m
Jane Hsiao
Vice Chairman & Chief Technical Officer17.8yrsUS$2.19m4.92%
$ 50.0m
Elias Zerhouni
President & Vice Chairman2.6yrsUS$2.19m3.03%
$ 30.8m
Adam Logal
Senior VP17.8yrsUS$1.81m0.027%
$ 270.5k
Steven Rubin
Executive VP of Administration & Director17.6yrsUS$1.94m0.92%
$ 9.3m
Akhtar Ashfaq
Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal7.8yrsno datano data
Gary Nabel
Chief Innovation Officer & Director2.6yrsno data5.99%
$ 60.9m
Giovanni Abbadessa
Chief Medical Officerless than a yearno datano data
Charles Bishop
Chief Executive Officer of OPKO Renal11.8yrsno datano data
Antonio Cruz
President of Transition Therapeuticsno datano datano data
Hans Berner
President of OPKO Health Iberoamericano datano datano data
Damien Burke
Chief Executive Officer of EirGen Pharma5.1yrsno datano data

9.8yrs

Average Tenure

71.5yo

Average Age

Experienced Management: 0KCS's management team is seasoned and experienced (9.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO17.8yrsUS$2.28m36.6%
$ 371.8m
Jane Hsiao
Vice Chairman & Chief Technical Officer17.8yrsUS$2.19m4.92%
$ 50.0m
Elias Zerhouni
President & Vice Chairman2.6yrsUS$2.19m3.03%
$ 30.8m
Steven Rubin
Executive VP of Administration & Director17.8yrsUS$1.94m0.92%
$ 9.3m
Gary Nabel
Chief Innovation Officer & Director2.6yrsno data5.99%
$ 60.9m
Roger Medel
Independent Director4yrsUS$69.90k0%
$ 0
Richard Pfenniger
Lead Independent Director16.9yrsUS$134.80k0.048%
$ 490.8k
Richard Krasno
Independent Director7.8yrsUS$92.40k0.015%
$ 156.0k
John Paganelli
Independent Director21yrsUS$84.90k0.058%
$ 594.2k
Prem Lachman
Independent Director3.8yrsUS$92.40k0%
$ 0
Lin-Tsing Yu
Independent Director15.7yrsUS$62.40k0.0099%
$ 100.4k

15.7yrs

Average Tenure

77yo

Average Age

Experienced Board: 0KCS's board of directors are seasoned and experienced ( 15.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 00:34
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OPKO Health, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Louise ChenCantor Fitzgerald & Co.
Dana FlandersGuggenheim Securities, LLC